{"disease":{"id":"chronic-idiopathic-thrombocytopenic-purpura","name":"Chronic idiopathic thrombocytopenic purpura","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":4,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"romiplostim","indication_name":"Chronic idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nplate","generic_name":"ROMIPLOSTIM","company_name":"Amgen","drug_phase":"marketed","molecular_target":"Thrombopoietin receptor","drug_class":"Thrombopoietin Receptor Agonist [EPC]","quality_score":70,"revenue":"1524.0","mechanism":"Nplate works by binding to the thrombopoietin receptor to stimulate platelet production."},{"drug_id":"eltrombopag","indication_name":"Chronic idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Promacta","generic_name":"ELTROMBOPAG","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Thrombopoietin receptor","drug_class":"Thrombopoietin Receptor Agonist","quality_score":80,"revenue":"569","mechanism":"Promacta works by binding to the thrombopoietin receptor, stimulating platelet production in the bone marrow."},{"drug_id":"fostamatinib","indication_name":"Chronic idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tavalisse","generic_name":"FOSTAMATINIB","company_name":"Rigel Pharms","drug_phase":"marketed","molecular_target":"Receptor-type tyrosine-protein kinase FLT3","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Tavalisse works by blocking the activity of the FLT3 enzyme, which is involved in the production of platelets."},{"drug_id":"nplate","indication_name":"Chronic idiopathic thrombocytopenic purpura","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Nplate","company_name":"Nantes University Hospital","drug_phase":"marketed","molecular_target":"Thrombopoietin receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04071496","title":"Diagnostic of Chronic Thrombocytopenia","phase":"","overall_status":"COMPLETED","enrollment_count":158,"lead_sponsor_name":"University Hospital, Bordeaux","has_results":false},{"nct_id":"NCT06757257","title":"Special Drug Use-results Survey for Long-term Use (Fostamatinib)","phase":"","overall_status":"RECRUITING","enrollment_count":149,"lead_sponsor_name":"Kissei Pharmaceutical Co., Ltd.","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}